AR108890A1 - Inhibidores de la entrada del cmvh - Google Patents

Inhibidores de la entrada del cmvh

Info

Publication number
AR108890A1
AR108890A1 ARP170101770A ARP170101770A AR108890A1 AR 108890 A1 AR108890 A1 AR 108890A1 AR P170101770 A ARP170101770 A AR P170101770A AR P170101770 A ARP170101770 A AR P170101770A AR 108890 A1 AR108890 A1 AR 108890A1
Authority
AR
Argentina
Prior art keywords
cmvh
pdgfr
subject
infected
input inhibitors
Prior art date
Application number
ARP170101770A
Other languages
English (en)
Inventor
Barbara Adler
Cora Stegmann
Kerstin Laib Sampaio
Christian Sinzger
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Anti Infective Cures Gmbh filed Critical Aicuris Anti Infective Cures Gmbh
Publication of AR108890A1 publication Critical patent/AR108890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Es materia objeto de la presente una quimera PDGFR-a-Fc soluble o un péptido derivado de PDGFR-a o un anticuerpo anti-PDGFR-a o un fragmento de anticuerpo frente a PDGFR-a o un armazón no Ig anti-PDGFR-a para la inhibición de la entrada del CMVH para su uso en un método de tratamiento en un sujeto que ha sido infectado por el CMVH o para su uso en un método de profilaxis de una infección por el CMVH en un sujeto que aún no ha sido infectado por el CMVH.
ARP170101770A 2016-06-27 2017-06-28 Inhibidores de la entrada del cmvh AR108890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16176520 2016-06-27

Publications (1)

Publication Number Publication Date
AR108890A1 true AR108890A1 (es) 2018-10-10

Family

ID=56289338

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101770A AR108890A1 (es) 2016-06-27 2017-06-28 Inhibidores de la entrada del cmvh

Country Status (6)

Country Link
US (2) US11390661B2 (es)
EP (1) EP3474887A1 (es)
AR (1) AR108890A1 (es)
CA (1) CA3028859A1 (es)
MA (1) MA45493A (es)
WO (1) WO2018002081A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
US20220380436A1 (en) * 2019-09-17 2022-12-01 The Board Of Trustees Of The University Of Illinois Engineered receptors for human cytomegalovirus and uses thereof
WO2022013304A1 (en) 2020-07-14 2022-01-20 Aicuris Gmbh & Co. Kg PDGFRα POLYPEPTIDES AS VIRAL DECOY RECEPTORS
JP2024512253A (ja) * 2021-02-22 2024-03-19 ジェネンテック， インコーポレイテッド 宿主細胞の表面とヘルペスウイルスとの相互作用を調節するための方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
WO2003020746A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
EP1941867B1 (en) 2002-06-07 2011-10-12 Dyax Corp. Modified kunitz domain polypeptide
EP1626988A2 (en) * 2003-05-16 2006-02-22 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
CA2560046A1 (en) * 2004-03-16 2005-09-22 Dnavec Research Inc. Methods for suppressing tumor proliferation
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
PT2100614E (pt) 2005-06-17 2013-12-16 Imclone Llc Antagonistas de receptor para tratamento de cancro ósseo metastático
WO2009021150A2 (en) 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
JP5954990B2 (ja) 2008-11-03 2016-07-20 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
AU2010288542B2 (en) 2009-08-27 2014-05-22 Covagen Ag IL-17 binding compounds and medical uses thereof
WO2011053798A2 (en) 2009-10-30 2011-05-05 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
ES2441803T3 (es) 2009-12-14 2014-02-06 Scil Proteins Gmbh Un método para identificar proteínas de ubicuitina heteromultímeras modificadas con capacidad para unirse a ligandos
HUE043835T2 (hu) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh IL-4 receptor-alfát kötõ könny-lipokalin muteinek
RU2014140116A (ru) 2012-04-24 2016-06-10 Тромбодженикс Н.В. Антитела против pdgf-c

Also Published As

Publication number Publication date
US20190161532A1 (en) 2019-05-30
CA3028859A1 (en) 2018-01-04
EP3474887A1 (en) 2019-05-01
US11390661B2 (en) 2022-07-19
WO2018002081A1 (en) 2018-01-04
MA45493A (fr) 2019-05-01
US20210380664A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
AR108890A1 (es) Inhibidores de la entrada del cmvh
CL2016000400A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
CR20170219A (es) Inhibidores del bromodominio
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CY1123221T1 (el) Ενωσεις θειαζολιδιου για αντιμετωπιση ιογενων λοιμοξεων
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
CL2017003133A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
EP4342545A3 (en) Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
CR20170005A (es) Derivados de insoindolina
AR105335A1 (es) Anticuerpos monoclonales anti-sortilina
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода

Legal Events

Date Code Title Description
FB Suspension of granting procedure